Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 15/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.41 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043761 | 0.88 | CCR2 (0.45) | CCR2KCNH2TACR1 | |
| SCHEMBL3023181 | 0.88 | CCR2 (0.45) | CCR2KCNH2TACR1 | |
| SCHEMBL3033045 | 0.85 | CCR2 (0.44) | CCR2KCNH2TACR1 | |
| SCHEMBL3029490 | 0.84 | NPSR1 (0.49) | CCR2KCNH2ALDH1A1 | |
| SCHEMBL3029508 | 0.84 | CCR2 (0.44) | CCR2KCNH2ALDH1A1 | |
| SCHEMBL3038771 | 0.83 | CCR2 (0.44) | CCR2KCNH2TACR1ALDH1A1 | |
| SCHEMBL3029680 | 0.83 | CCR2 (0.44) | CCR2KCNH2TACR1ALDH1A1 | |
| SCHEMBL3039474 | 0.83 | CCR2 (0.44) | CCR2KCNH2TACR1ALDH1A1 | |
| SCHEMBL3791058 | 0.83 | CCR2 (0.44) | CCR2KCNH2TACR1 | |
| SCHEMBL3038733 | 0.83 | KCNH2 (0.47) | CCR2KCNH2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | claimed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | CCR2, CCR1, CCR5 | CCR2 1/4885KCNH2 4417/4885TACR1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.